Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/182)
-
Patent number: 8975243Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: GrantFiled: November 30, 2012Date of Patent: March 10, 2015Assignee: The Regents of the University of CaliforniaInventors: Ranjan Dohil, John Bastian, Seema S. Aceves
-
Patent number: 8975246Abstract: A method for treating a disease or disorder associated with altered glucose metabolism or insulin action in a subject in need thereof. The method includes administering to the subject a BAFAC (bile acid or bile salt fatty acid conjugate) of general formula II: W-X-G in which G is a bile acid or bile salt radical, which is optionally conjugated in position 24 with a suitable amino acid, W stands for one or two fatty acid radicals, each having from 14-22 carbon atoms, and X is a suitable bonding member or a direct C?C bond between G and each W, said suitable bonding member being selected from the group consisting of NH, O, P and S. The disease or disorder associated with altered glucose metabolism is selected from the group consisting of hyperglycemia, diabetes, insulin resistance and obesity.Type: GrantFiled: February 6, 2012Date of Patent: March 10, 2015Assignee: Galmed Research and Development Ltd.Inventor: Beatrice Gilat
-
Patent number: 8968763Abstract: Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes.Type: GrantFiled: February 19, 2010Date of Patent: March 3, 2015Assignee: Medtronic Vascular, Inc.Inventors: Ya Guo, Peiwen Cheng
-
Patent number: 8969326Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.Type: GrantFiled: January 18, 2012Date of Patent: March 3, 2015Assignee: University of Pittsburgh—Of The Commonwealth System Of Higher EducationInventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
-
Patent number: 8969330Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.Type: GrantFiled: February 7, 2013Date of Patent: March 3, 2015Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 8969329Abstract: Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3?-hydroxy-5?-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning.Type: GrantFiled: June 11, 2008Date of Patent: March 3, 2015Assignee: University of Southern CaliforniaInventors: Roberta Diaz Brinton, Jun Ming Wang
-
Publication number: 20150051182Abstract: Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.Type: ApplicationFiled: August 27, 2014Publication date: February 19, 2015Inventors: Michael S. Kolodney, Adam M. Rotunda
-
Publication number: 20150051178Abstract: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.Type: ApplicationFiled: July 16, 2014Publication date: February 19, 2015Inventor: Rhonda R. Voskuhl
-
Patent number: 8957055Abstract: Sterol derivatives of formula (I) and a method for the production of the compounds, a medicament using one of the compounds and a pharmaceutical composition comprising the medicament.Type: GrantFiled: August 28, 2013Date of Patent: February 17, 2015Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Marc Poirot, Philippe De Medina, Sandrine Poirot
-
Patent number: 8957054Abstract: Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.Type: GrantFiled: July 9, 2012Date of Patent: February 17, 2015Assignee: Endorecherche, Inc.Inventor: Fernand Labrie
-
Publication number: 20150045335Abstract: According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.Type: ApplicationFiled: October 22, 2014Publication date: February 12, 2015Inventors: Brian A. Bernick, Thorsteinn Thorsteinsson, Peter H. R. Persicaner, Janice Louise Cacace, Frederick D. Sancilio
-
Publication number: 20150044285Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.Type: ApplicationFiled: October 27, 2014Publication date: February 12, 2015Inventors: Brendan MULDOON, Ryan Gerald LOUGHLIN, Gerarde SWEENEY, Emma Karen BOYD
-
Patent number: 8951996Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.Type: GrantFiled: July 28, 2011Date of Patent: February 10, 2015Assignee: Lipocine Inc.Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Chidambaram Nachiappan, Mahesh V. Patel
-
Patent number: 8951995Abstract: The present invention relates to the use of nor-ursodeoxycholic acid for the manufacture of a drug for the treatment and/or the prevention of liver diseases, preferably chronic liver diseases.Type: GrantFiled: May 12, 2005Date of Patent: February 10, 2015Assignee: Medizinische Universitat GrazInventors: Michael Trauner, Alan Hofmann, Peter Fickert
-
Publication number: 20150038468Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.Type: ApplicationFiled: October 20, 2014Publication date: February 5, 2015Inventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
-
Patent number: 8946199Abstract: Zoledronic Acid is used for treatment of hypercalcemia of malignancy, for the treatment of bone metastasis associated with malignancies such as prostate and breast cancer, for the prevention of and treatment of osteoporosis and for the treatment of Paget's disease. Administration of Zoledronic Acid is complicated by what is described as “post-dosing syndrome” (PDS) and osteonecrosis of the jaw (ONJ). Inflammation may be the cause of these side effects, which could be decreased by the co-administration of steroids. This application is a method of use patent for the co-administration of steroids (oral, IV, IM, rectal, or by inhalation) with Zoledronic Acid and a composition of matter patent for mixing Methyl Prednisolone with Zoledronic Acid for infusion.Type: GrantFiled: April 26, 2010Date of Patent: February 3, 2015Inventor: Ketan Desai
-
Publication number: 20150030543Abstract: The present invention relates to a formulation of a therapeutic or diagnostic agent in the form of a nano-emulsion, to its preparation method and to the use of this formulation for treating or diagnosing hormone-dependent cancers or cancers of organs synthesizing steroidal hormones.Type: ApplicationFiled: September 26, 2012Publication date: January 29, 2015Applicant: Commissariat à l'énergie atomique et aux énergies alternativesInventors: Juliette Merian, Raphaël Boisgard, Bertrand Tavitian, Isabelle Texier-Nogues
-
Patent number: 8936809Abstract: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.Type: GrantFiled: March 31, 2006Date of Patent: January 20, 2015Assignee: Lidds ABInventors: Hans Lennernäs, Bo Lennernäs, Jonas Hugosson, Niklas Axén
-
Publication number: 20150018327Abstract: Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a ?-cyclodextrin, e.g., a sulfo butyl ether ?-cyclodextrin, e.g., a ?-cyclodextrin, e.g., a sulfo butyl ether ?-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders.Type: ApplicationFiled: January 23, 2013Publication date: January 15, 2015Inventor: Kiran Reddy
-
Publication number: 20150018326Abstract: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Applicant: CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Xi Jiang, Ming Tan, Xufu Zhang
-
Publication number: 20150018322Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.Type: ApplicationFiled: July 11, 2014Publication date: January 15, 2015Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
-
Patent number: 8933063Abstract: The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment of bacterial infections.Type: GrantFiled: October 30, 2006Date of Patent: January 13, 2015Assignee: Leo Pharma A/SInventors: Jan Jensen, Niels Rastrup Andersen
-
Patent number: 8932614Abstract: A composite that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 ?m, 50 nm to 10 ?m, 100 nm to 5 ?m, or 1 ?m to 10 ?m. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time.Type: GrantFiled: August 24, 2012Date of Patent: January 13, 2015Inventors: Paul B. Savage, Carl Genberg
-
Publication number: 20150005274Abstract: The present invention relates to the use of a compound chosen from squalamine and a squalamine-analogue aminosteroid compound as agent for disinfecting an inert material object, in particular for the pre-disinfection of medical, dental, diagnostic or surgical equipment. The present invention also provides an aqueous or water-soluble disinfecting composition beneficial for a use according to the invention, characterized in that as disinfecting active compound it comprises a said antibacterial and antifungal compound selected from squalamine and a said squalamine-analogue aminosteroid compound and suitable excipients for a water-soluble or aqueous formulation.Type: ApplicationFiled: January 4, 2013Publication date: January 1, 2015Inventors: Jean-Michel Brunel, Didier Raoult, Jean-Marc Rolain
-
Publication number: 20150004106Abstract: A topical skin care method for acne and subcutaneous gland disorders utilizing a composition utilizing beta-sitosterol in conjunction with a dermatologically acceptable vehicle such as a lotion, gel, or cream. In some embodiments a sunscreen agent is also used to reduce skin exposure to ultraviolet rays. In yet another embodiment an antifungal medication additionally applied with the beta-sitosterol and dermatological vehicle to provide enhanced treatment of the acne and associated skin conditions.Type: ApplicationFiled: June 26, 2013Publication date: January 1, 2015Inventor: Jordan Austin
-
Publication number: 20150005273Abstract: The present invention relates to the use of avocado peels in order to obtain avocado unsaponifiable enriched in saturated aliphatic hydrocarbons and in sterols, said avocado peels accounting for 5 to 50% by weight relative to the total weight of avocado used. The invention also relates to a method for obtaining avocado unsaponifiable enriched in saturated aliphatic hydrocarbons and in sterols from at least avocado peels, said avocado peels accounting for 5 to 50% by weight relative to the total weight of avocado used. The invention also relates to an avocado unsaponifiable enriched in saturated aliphatic hydrocarbons and in sterols, obtainable by this method. Lastly, the invention relates to an avocado unsaponifiable enriched in saturated aliphatic hydrocarbons and in sterols, for use as a drug, advantageously in the in the prevention and/or treatment of conjunctive tissue disorders such as arthrosis, articular pathologies such as rheumatism, or periodontal diseases such as gingivitis or periodontitis.Type: ApplicationFiled: January 14, 2013Publication date: January 1, 2015Inventors: Philippe Msika, Jacques Legrand, Sebastien Garnier
-
Publication number: 20140378426Abstract: The invention provides compositions of and methods for using estradiol and related compounds to improve visual function and to treat ocular degenerative disorders.Type: ApplicationFiled: June 20, 2014Publication date: December 25, 2014Inventor: Anne Hanneken
-
Publication number: 20140378424Abstract: The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (ERM), optionally, in combination with an anti-obesity or weight loss agent.Type: ApplicationFiled: December 31, 2012Publication date: December 25, 2014Inventors: Alexey G Ryazanov, Alexander V. Chikunov
-
Publication number: 20140377332Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.Type: ApplicationFiled: November 21, 2013Publication date: December 25, 2014Inventors: Florian N. Ludwig, Stephen D. Pacetti, Syed F.A. Hossainy, Dariush Davalian
-
Publication number: 20140370072Abstract: Provided herein is a prohealing piezoelectric coating and the method of making and using the same.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Syed Faiyaz Ahmed Hossainy, Mikael Trollsas, Lothar Walter Kleiner
-
Publication number: 20140371190Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.Type: ApplicationFiled: May 14, 2014Publication date: December 18, 2014Inventor: Roberto Pellicciari
-
Publication number: 20140371191Abstract: The present invention relates to low dose estradiol solutions for oromucosal administration suitable in replacement therapy or suppletion of low estradiol levels and also for preventing, alleviating or treating symptoms associated with low endogenous levels of estradiol in female subjects.Type: ApplicationFiled: January 4, 2013Publication date: December 18, 2014Inventor: Franciscus Wilhelmus Henricus Maria Merkus
-
Publication number: 20140370084Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.Type: ApplicationFiled: December 13, 2013Publication date: December 18, 2014Applicant: TherapeuticsMD, Inc.Inventors: Brian A. Bernick, Janice Louise Cacace, Peter H.R. Persicaner, Neda Irani, Julia M. Amadio
-
Publication number: 20140364405Abstract: A method for the treatment of seborrhoea in a patient comprises administering to the patient an effective amount of (24RS) or (24S) scymnol, an ester thereof or a pharmaceutically acceptable salt of a said ester, or of (24R) scymnol.Type: ApplicationFiled: December 14, 2012Publication date: December 11, 2014Applicant: MCFARLANE MARKETING (AUST.) PTY. LTD.Inventors: Theodore Macrides, Andrew Broadbent
-
Publication number: 20140364404Abstract: The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Inventors: Robert L. Cleek, Paul D. Drumheller, Theresa A. Holland
-
Patent number: 8895542Abstract: Disclosed is a medicinal cream that includes flisidic acid which is made in situ under an oxygen-free environment using sodium fusidate. The fusidic acid is made by dissolving the sodium fusidate in a co-solvent under inert gas purging and under vacuum, and converting the sodium fusidate to fusidic acid in situ by adding an acid under stirring, The disclosed medicinal cream also includes a biopolymer and a cream base comprising at least one of each of a primary and secondary emulsifier, a waxy material, and water.Type: GrantFiled: April 12, 2010Date of Patent: November 25, 2014Inventors: Vanangamudi Subramaniam Sulur, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Haridas Sankar, Kuppusamy Senthilkumar
-
Patent number: 8895541Abstract: This invention relates to Huntington's disease and more specifically to methods for inhibiting the development of or treating Huntington's disease by administering estrogen, testosterone, precursors thereof or combinations thereof.Type: GrantFiled: December 6, 2010Date of Patent: November 25, 2014Inventor: James A. Carnazza
-
Publication number: 20140343023Abstract: The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.Type: ApplicationFiled: September 18, 2012Publication date: November 20, 2014Inventors: Christian Wolfrum, Erick Carriera, Bettina Meissburger
-
Publication number: 20140343027Abstract: The present invention relates to the formulation of steroids, including neurosteroids (e.g., allopregnanolone (ALP)) in edible oils to enhance their absorption when administered, e.g., orally or transmucosally to a patient.Type: ApplicationFiled: September 21, 2012Publication date: November 20, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Michael A. Rogawski
-
Patent number: 8889662Abstract: The present invention includes methods of influencing the sex chromosome ovulated by a female bird and altering the sex ratio in avian offspring by altering the exposure of an ovulating female bird to one or more stress hormones. In some aspects, the method includes exposing an avian female to a glucocorticoid, such as for example, corticosterone, after the completion of rapid yolk deposition and prior to ovulation.Type: GrantFiled: March 1, 2010Date of Patent: November 18, 2014Assignee: University of Georgia Research Foundation, Inc.Inventor: Kristen J. Navara
-
Patent number: 8889840Abstract: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.Type: GrantFiled: October 29, 2010Date of Patent: November 18, 2014Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Young-Guen Kwon, Young-Ger Suh
-
Publication number: 20140336131Abstract: Disclosed herein are methods of treating, reducing, or preventing a disease such as oral mucositis, gastric mucositis, or inflammatory fibrosis, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.Type: ApplicationFiled: July 25, 2014Publication date: November 13, 2014Applicant: BRIGHAM YOUNG UNIVERSITYInventors: Paul B. Savage, Carl A. Genberg
-
Patent number: 8883769Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.Type: GrantFiled: November 18, 2010Date of Patent: November 11, 2014Assignee: White Mountain Pharma, Inc.Inventors: Hillary D. White, Robert Gyurik
-
Patent number: 8883770Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: January 14, 2013Date of Patent: November 11, 2014Assignee: Kythera Biopharmaceuticals, Inc.Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Publication number: 20140328928Abstract: An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.Type: ApplicationFiled: July 22, 2014Publication date: November 6, 2014Inventors: Christopher J. Milley, Scott E. Peters
-
Publication number: 20140329789Abstract: This invention relates to Huntington's disease and more specifically to methods for inhibiting the development of or treating Huntington's disease by administering estrogen, testosterone, precursors thereof or combinations thereof.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventor: James A. Carnazza
-
Publication number: 20140329790Abstract: Disclosed is the use of 5?-androstane-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.Type: ApplicationFiled: July 15, 2014Publication date: November 6, 2014Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL LTD.Inventors: Guangmei YAN, Haiyan HU, Tiandong LENG, Hanfei SANG, Jingxia ZHANG, Pengxin QIU, Shujia ZHOU, Jiesi CHEN, Xiuhua YOU
-
Publication number: 20140328792Abstract: A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect.Type: ApplicationFiled: May 9, 2014Publication date: November 6, 2014Inventor: Michael Zasloff
-
Publication number: 20140323455Abstract: Provided are methods for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a hydrophilic bile acid (e.g., UDCA or TUDCA) to a mammal having an eye with a detached retina. Administration of the hydrophilic bile acid maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid, thereby minimizing the loss of vision or visual acuity, which otherwise may occur as a result of the retinal detachment.Type: ApplicationFiled: August 15, 2012Publication date: October 30, 2014Applicant: MASSACHUSETTS EYE AND EAR INFIRMARYInventor: Demetrios G. Vavvas
-
Publication number: 20140323456Abstract: The present disclosure relates to esters of 8-[2-(2-pentyl-cyclopropylmethyl)cyclopropyl]-octanoic acid (“DCPLA”). The disclosure further relates to compositions, kits, and methods for treatment using the esters.Type: ApplicationFiled: November 13, 2012Publication date: October 30, 2014Inventors: Daniel L. Alkon, Thomas J. Nelson